Scientific presentations demonstrate argenx Leadership in FcRn blockade and commitment to innovationng to the patient across several neuromuscular diseases
Additional data from the open-label ADAPT+ study support the long-term safety of VYVGART® (efgartigimod alfa–fcab) for the treatment of adult patients with generalized mjasthenia Gravis (gMG) who saw consistent improvements in function and strength several years
Pooled Data from ADAPT Studies and real clinical environment recommend VYVGART Treatment was associated with clinical significance illness value improvements at seronegative gMG Patientlys
Amsterdamthe Netherlands – September 21, 2022 argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company dedicated to improving the lives of people living with serious autoimmune diseases, announced today the presentation of new data from its neuromuscular franchise at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (21st 2022) and of the Myasthenia Gravis Foundation of America (MGFA) Scientific Session (September 21, 2022), both being held in Nashville, TN.
“We have a long-term commitment to the gMG community to reach as many people as possible living with this devastating disease and provide them with a new standard of care. The data we are presenting this week underscores that commitment as we continue to gather clinical safety and efficacy data on VYVGART, our world-class FcRn blocker and the anchor of our neuromuscular franchise. gMG is a disease that affects every patient differently, and every patient is unique we want to approach treatment – meeting the needs of patients and physicians based on their individual disease experience,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “Deeper within our neuromuscular franchise, we leverage the thoughtful study designs of the ADHERE study of efgartigimod CIDP and the ARDA study of ARGX-117 at MMN, which gave us…
